ESTRO 2024 - Abstract Book

S1836

Clinical - Mixed sites, palliation

ESTRO 2024

Figure 1 . Mean quality of life scores in three domains of the C15-PAL questionnaire in the different patient groups: short survivors (surviving <3 months), moderate survivors (surviving ≥3 months and <2 years), long survivors (surviving ≥2 years), and extended survivors (surviving ≥5 years). A higher score depicts an improved quality of life. Normative data show the mean score of the general, cancer-free population. C15-PAL = Quality of Life Questionnaire Core 15 Palliative Care.

Conclusion:

The PRESENT cohort represents the first cohort of patients with bone metastases featuring follow-up periods up to 10 years. A substantial proportion (31%) of patients referred for radiotherapy of bone metastases survives more than 2 years with good global quality of life and emotional functioning. Very long survivors (8%, surviving ≥ 5 years) additionally report very good physical functioning.

Keywords: Bone metastases, quality of life, radiotherapy

298

Digital Poster

A single centre audit of 403 patients undergoing whole brain radiotherapy for cerebral metastases.